The Effect of Age on Prostate Implantation Results
Authors:
- Anwar KhanAKAnwar Khan
- John ColbergJCJohn Colberg
- Lynn D. WilsonLWLynn D. Wilson
- 1 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 12 (4) , 305-308
Abstract
The current study was undertaken to determine the effect of young age (60 years or younger) on the 5-year biochemical disease-free survival rate following ultrasound-guided transperineal prostate implantation. The radiation therapy charts of 330 patients who underwent ultrasound-guided transperineal prostate implantation who were treated from 1992 through 2004 were retrospectively reviewed. Follow-up ranged from 12 to 120 months, with a mean of 48 months. A total of 63 patients were 60 years of age or younger, and 267 patients were over 60 years of age. Prostate-specific antigen (PSA) recurrence was defined as three successive increases following ultrasound-guided transperineal prostate implantation. Biochemical disease-free survival was determined using the life-table method. There were no statistically significant differences in the 5-year biochemical disease-free survival rates for the younger versus the older group. On univariate analysis, age was not a statistically significant factor in predicting PSA failure. Univariate analysis revealed that Gleason score, PSA at diagnosis, and clinical T stage were significant in predicting for PSA failure. Patients with Gleason score < 7, PSA < 10, and clinical stage T1c disease had statistically significant lower PSA failure rates than patients with Gleason score < 7, PSA < 10, and clinical stage T2 disease, respectively. Patients who are 60 years of age or younger who are treated with ultrasound-guided transperineal prostate implantation can expect 5-year biochemical disease-free survival rates similar to those of older patients treated with ultrasound-guided transperineal prostate implantation therapy.Keywords
This publication has 16 references indexed in Scilit:
- Radical Prostatectomy versus Watchful Waiting in Early Prostate CancerNew England Journal of Medicine, 2005
- Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancerUrology, 2004
- Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancerThe Lancet Oncology, 2003
- Practical application of biochemical failure definitions: what to do and when to do itInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- ERA SPECIFIC BIOCHEMICAL RECURRENCE-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 2001
- The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinomaRadiotherapy and Oncology, 2000
- Optimum timing for image-based dose evaluation of 125I and 103Pd prostate seed implantsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Long-term complications with prostate implants: Iodine-125 vs. palladium-103Radiation Oncology Investigations, 1999
- Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implantsMedical Physics, 1998
- Maximum utilization of the life table method in analyzing survivalJournal of Chronic Diseases, 1958